Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392241 | 0.84 | CA12 (0.53) | CA12CA9PARP1GRM5CLK4 | |
| SCHEMBL393532 | 0.81 | PARP10 (0.56) | PARP1GRM5PARP10PARP11PDPK1 | |
| SCHEMBL12496250 | 0.78 | PARP10 (0.44) | CA12CA9PARP1GRM5GSK3B | |
| SCHEMBL1443936 | 0.76 | — | — | |
| Water SCHEMBL19462837 | 0.72 | CA12 (0.95) | CA12CA9PARP1GRM5CLK4 | |
| Water SCHEMBL19462703 | 0.72 | CA12 (0.95) | CA12CA9PARP1GRM5CLK4 | |
| SCHEMBL16907888 | 0.72 | CA12 (0.48) | CA12CA9PARP1GRM5CLK4 | |
| Water SCHEMBL19462706 | 0.72 | CA12 (0.95) | CA12CA9PARP1GRM5CLK4 | |
| Hydrochloric Acid SCHEMBL29374879 | 0.71 | CA12 (0.91) | CA12CA9PARP1GRM5CLK4 | |
| SCHEMBL26613464 | 0.71 | AHR (0.31) | CA12CA9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | claimed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | claimed |
| EP-4199911-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN Pharmaceutica NV (BE) | 2023-06-28 | — | — | EP | claimed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | claimed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4061966-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| EP-4062175-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2015073804-A2 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-21 | — | — | WO | claimed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | claimed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | claimed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| EP-2516438-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | claimed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | CA12 2407/4885CA9 1199/4885PARP1 2424/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | CA12 4507/4885CA9 4728/4885PARP1 941/4885 |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | CA12 754/4885CA9 648/4885PARP1 130/4885 |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | CA12 2981/4885CA9 4767/4885PARP1 698/4885 |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | CA12 4870/4885CA9 3375/4885PARP1 1277/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | CA12 3779/4885CA9 3661/4885PARP1 1712/4885 |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | CA12 1946/4885CA9 2125/4885PARP1 2884/4885 |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | CA12 1946/4885CA9 2125/4885PARP1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.